Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
LegalNovember 17, 2026

Foley & Lardner Warns Device Makers on U.S. Compliance Risk

In a Foley & Lardner LLP client alert, the firm argues that medical device companies entering the U.S. market should prioritize corporate compliance programs given active DOJ and HHS-OIG enforcement under the False Claims Act, Anti-Kickback Statute, and Foreign Corrupt Practices Act. The firm cites settlements including ResMed ($37.5 million, 2020), Innovasis ($12 million, 2024), Aesculap Implant Systems ($38.5 million, 2025), and Diopsys ($14.25 million, 2025), covering kickbacks to providers, off-label promotion, and false claims to Medicare and Medicaid. The firm recommends building compliance programs around OIG's seven elements and focusing on provider financial relationships, promotional and billing practices, distributor oversight, and transfer-of-value reporting.

Why it mattersMedical device manufacturers and their executives entering the U.S. market may face significant False Claims Act and Anti-Kickback Statute liability tied to Medicare and Medicaid billing if compliance programs are not established early.

Finance

Read the full article at foley.com →
Share this briefing

You might also like

← All stories

Get the daily briefing.